The role of adiponectin and cytokines in Amyotrophic lateral sclerosis: assessment of disease progression and survival status Authors: Jing Zhang, Mei Tian, Tongyang Niu, Rui Li, Qi Liu, Man Liu, Xiaomeng Zhou, Hui Dong, Yaling Liu Published: 2026 ABSTRACT Amyotrophic lateral sclerosis (ALS) is a fatal, progressive neurodegenerative disorder. ALS typically progresses rapidly, leading to respiratory failure within 3 to 5 years of symptom onset. Identifying risk factors that influence disease progression and survival is critical for enhancing management strategies. The present study therefore investigated the roles of inflammatory factors and adipokines (especially adiponectin) in the progression and prognosis of ALS. The study included 80 ALS patients, with a follow-up period of 1.5 years. Survival analysis was performed using a Cox regression, with hazard ratios (HR) and 95% confidence intervals (CI) presented via forest plots. Our results indicated that ALS patients in the fast-progressing group exhibited lower levels of adiponectin (p < 0.001) and IL-10 (p < 0.001). The Cox regression and forest plot results suggest the potential of adiponectin (HR = 0.905, 95%CI: 0.866–0.946, p < 0.001), IL-10 (HR = 0.968, 95%CI: 0.951–0.986, p < 0.001), δFS (HR = 1.234, 95%CI: 1.065–1.430, p = 0.005) and ALSFRS-R (HR = 0.820, 95%CI: 0.765–0.878, p < 0.001) as potential risk factors. In addition, these risk factors are significantly associated with poor survival prognosis in high-risk populations (all p < 0.001). This study identifies adiponectin, IL-10, ALSFRS-R, and δFS as key risk factors influencing ALS progression and prognosis.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54291-9. Introduction Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease affecting motor neurons in the brain, brainstem, and spinal cord1,2. The disease typically progresses rapidly, with most patients succumbing to respiratory failure within 3–5 years of symptom onset3. ALS pathogenesis involves multiple factors, including oxidative stress, glutamate excitotoxicity, disruptions in protein homeostasis, RNA processing defects, impaired axonal transport, and mitochondrial dysfunction4. However, the precise mechanisms underlying ALS remain unclear, and no effective treatments currently exist to delay or prevent its onset and progression. Identifying risk factors that can influence disease progression and survival is critical for improving management strategies. Recent studies have raised increasing concern about the critical role of inflammation in the development of central neurodegenerative diseases, including ALS5. Inflammation not only results from neurodegenerative diseases but also contributes significantly to their progression. Notably, inflammation occurs even before abnormal protein aggregation in ALS6. Research has shown elevated levels of inflammatory mediators in ALS patients, such as IL-6, IL-1β, and TNF-α, which are closely associated with disease progression and prognosis7–11. These studies suggest that indexes of systemic inflammation could be useful biomarkers related to disease progression in ALS12. This relationship between inflammation and ALS progression has led researchers to propose that specific inflammatory biomarkers could serve as valuable indicators for monitoring disease progression and assessing therapeutic efficacy. As is well known, rapid weight loss is associated with worse disease outcomes in ALS, and fat mass loss correlates with faster disease progression13. It is evident that the fat content and lipid metabolism of patients is significant factors in determining the progression of ALS disease. Mounting evidence highlights the role of adipose tissue in the development of a systemic inflammatory state. In addition to cytokines, adipokines also play crucial roles in regulating various physiological processes such as metabolism, inflammation, and immune function14. Adiponectin is the most abundant adipokine in the body and is a key player in the signaling network of adipose tissue15. Accumulating evidence suggests that adiponectin-mediated modulation of macrophage function and phenotype contributes to its role in controlling inflammation. Although there have been reports indicating the dual and opposite effects of adiponectin on neuroinflammation16,17, oxidative stress, and neuronal apoptosis, the role of adiponectin in the occurrence, development, and prognosis of ALS remains to be elucidated. This study aims to investigate the effects of inflammatory factors and adipokines, with a particular emphasis on adiponectin, on the progression and survival of ALS. By examining the relationship between adiponectin, related inflammatory factors, and ALS, we aim to identify risk factors or therapeutic targets that could provide new approaches to managing ALS. Results Demographics and clinical characteristics Participants were selected based on inclusion and exclusion criteria (Fig. 1), resulting in data collection from 80 ALS patients at the Second Hospital of Hebei Medical University, including 48 males and 32 females. Demographic characteristics of the sample are presented in Table 1. Subsequently, ALS patients were divided into two groups based on their δFS: the fast group and the slow group. The results indicated a substantial decline in adipokine (adiponectin, p < 0.001) expression in the fast group, accompanied by a significant increase in pro-inflammatory factors (IL-1β, IL-2, IL-6, IL-8 and TNF-α, all p < 0.001) and a significant reduced in anti-inflammatory factor (IL-10, p < 0.001) expression. Despite no significant alterations in baseline ALSFRS-R and δFS scores between the rapid and slow groups, a 1.5-year follow-up revealed a significant decline in ALSFRS-R scores (p < 0.001) and a significant increase in δFS (p < 0.001) in the rapid group. The findings suggest that ALS patients experiencing rapid progression exhibit lower levels of adiponectin and anti-inflammatory factors, and higher levels of pro-inflammatory factors (Table 2). Fig. 1Flow diagram of study design. Flow diagram of study design. Table 1Demographic and clinical characteristics comparison between the ALS group, slow group and the fast group.CharacteristicALS patients (N = 80)Slow group (N = 31)Fast group (N = 49)Age (year)59.17 ± 10.3558.65 ± 11.0159.51 ± 10.01BMI (kg/m2)22.99 ± 3.8424.00 (3.41)22.10 (6.68)Diagnostic delay (month)11.50 (12.00)12.00 (17.50)11.00 (9.00)Sex (n) Male48 (60.0%)19 (61.3%)29 (59.2%) Female32 (40.0%)12 (39.7%)20 (41.8%)*Site of onset (n) Limb58 (72.5%)20 (64.5%)38 (77.6%) Bulbar18 (22.5%)9 (29.0%)9 (18.4%) Mixed4 (5.0%)2 (6.5%)2 (4.0%) ALSFRS-R38.00 (12.00)38.00 (9.50)38.00 (10.00) ALSFRS-R-1.5 years13.00 (25.00)28.00 (8.00)0.00 (11.00)*** δFS0.83 (1.18)0.67 (1.08)0.88 (1.33) δFS-1.5 years1.47 (2.02)0.67 (0.39)2.50 (2.39)***Adipokines Adiponectin (ng/ml)53.52 (25.59)66.89 (8.29)41.18 (15.05)*** Visfatin (ng/ml)4.28 (2.16)4.17 (2.11)4.34 (2.21) Resistin (ng/ml)2.67 (1.50)2.73 (1.77)2.67 (1.32) Chemerin (ng/ml)2.50 (1.41)2.71 (0.93)2.35 (1.53) FGF-21 (pg/ml)453.98 (290.25)442.34 (298.53)468.88 (267.99)Pro-inflammatory cytokines IL-1β (pg/ml)319.23 (104.33)254.12 ± 38.40349.87 ± 41.03*** IL-2 (pg/ml)306.18 (89.05)249.15 ± 26.86343.43 ± 38.93*** IL-6 (pg/ml)122.17 (41.60)91.75 (43.19)131.82 (31.23)*** IL-8 (pg/ml)326.05 (133.56)256.15 (41.25)377.90 (75.31)*** TNF-α (pg/ml)336.64 (100.58)276.75 (82.82)381.28 (68.10)***Anti-inflammatory cytokine IL-4 (pg/ml)462.66 (167.92)474.03 (216.65)458.12 (155.44) IL-13 (pg/ml)224.64 (116.74)246.05 (109.44)214.27 (98.03) TGF-β (pg/ml)496.17 (228.77)550.20 (157.35)460.77 (286.98)IL-10 (pg/ml)104.25 (51.01)135.19 (31.18)85.74 (38.17)**** p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. Table 1Demographic and clinical characteristics comparison between the ALS group, slow group and the fast group.CharacteristicALS patients (N = 80)Slow group (N = 31)Fast group (N = 49)Age (year)59.17 ± 10.3558.65 ± 11.0159.51 ± 10.01BMI (kg/m2)22.99 ± 3.8424.00 (3.41)22.10 (6.68)Diagnostic delay (month)11.50 (12.00)12.00 (17.50)11.00 (9.00)Sex (n) Male48 (60.0%)19 (61.3%)29 (59.2%) Female32 (40.0%)12 (39.7%)20 (41.8%)*Site of onset (n) Limb58 (72.5%)20 (64.5%)38 (77.6%) Bulbar18 (22.5%)9 (29.0%)9 (18.4%) Mixed4 (5.0%)2 (6.5%)2 (4.0%) ALSFRS-R38.00 (12.00)38.00 (9.50)38.00 (10.00) ALSFRS-R-1.5 years13.00 (25.00)28.00 (8.00)0.00 (11.00)*** δFS0.83 (1.18)0.67 (1.08)0.88 (1.33) δFS-1.5 years1.47 (2.02)0.67 (0.39)2.50 (2.39)***Adipokines Adiponectin (ng/ml)53.52 (25.59)66.89 (8.29)41.18 (15.05)*** Visfatin (ng/ml)4.28 (2.16)4.17 (2.11)4.34 (2.21) Resistin (ng/ml)2.67 (1.50)2.73 (1.77)2.67 (1.32) Chemerin (ng/ml)2.50 (1.41)2.71 (0.93)2.35 (1.53) FGF-21 (pg/ml)453.98 (290.25)442.34 (298.53)468.88 (267.99)Pro-inflammatory cytokines IL-1β (pg/ml)319.23 (104.33)254.12 ± 38.40349.87 ± 41.03*** IL-2 (pg/ml)306.18 (89.05)249.15 ± 26.86343.43 ± 38.93*** IL-6 (pg/ml)122.17 (41.60)91.75 (43.19)131.82 (31.23)*** IL-8 (pg/ml)326.05 (133.56)256.15 (41.25)377.90 (75.31)*** TNF-α (pg/ml)336.64 (100.58)276.75 (82.82)381.28 (68.10)***Anti-inflammatory cytokine IL-4 (pg/ml)462.66 (167.92)474.03 (216.65)458.12 (155.44) IL-13 (pg/ml)224.64 (116.74)246.05 (109.44)214.27 (98.03) TGF-β (pg/ml)496.17 (228.77)550.20 (157.35)460.77 (286.98)IL-10 (pg/ml)104.25 (51.01)135.19 (31.18)85.74 (38.17)**** p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. Demographic and clinical characteristics comparison between the ALS group, slow group and the fast group. * p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. Table 2Comparison of basic characteristics, adipokines, and inflammatory factors between ALS survival and death groups.CharacteristicSurvival(N = 47)Death(N = 33)Age (year)59.74 ± 10.2858.36 ± 10.55BMI (kg/m2)23.88 (4.44)22.03 (6.68)Diagnostic delay (month)11.00 (9.50)12.00 (12.00)Sex (n) Male32 (68.1%)16 (48.5%) Female15 (31.9%)17 (51.5%)Site of onset (n) Limb34 (72.3%)24 (72.7%) Bulbar11 (23.4%)7 (21.2%) Mixed2 (4.3%)2 (6.1%) ALSFRS-R40.00 (8.00)31.00 (15.00)*** δFS0.58 (0.78)1.47 (1.67)***Adipokines Adiponectin (ng/ml)61.83 (14.86)39.23 (10.71)*** Visfatin (ng/ml)3.90 (2.20)4.56 (2.51) Resistin (ng/ml)2.73 (1.56)2.67 (1.37) Chemerin (ng/ml)2.67 (1.19)2.39 (1.57) FGF-21 (pg/ml)442.35 (209.25)534.72 (256.36)*Pro-inflammatory cytokines IL-1β (pg/ml)282.04 (72.12)362.60 (37.44)*** IL-2 (pg/ml)267.81 (66.64)349.68 (39.92)*** IL-6 (pg/ml)113.02 (46.17)129.96 (37.39)** IL-8 (pg/ml)282.24 (121.69)370.52 (83.39)*** TNF-α (pg/ml)300.70 (80.49)393.94 (50.17)***Anti-inflammatory cytokine IL-4 (pg/ml)488.50 (166.47)425.04 (169.07) IL-13 (pg/ml)209.98 (122.98)233.46 (73.35) TGF-β (pg/ml)522.13 (206.00)493.38 (288.60) IL-10 (pg/ml)128.37 (38.61)80.97 (37.52)**** p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. Table 2Comparison of basic characteristics, adipokines, and inflammatory factors between ALS survival and death groups.CharacteristicSurvival(N = 47)Death(N = 33)Age (year)59.74 ± 10.2858.36 ± 10.55BMI (kg/m2)23.88 (4.44)22.03 (6.68)Diagnostic delay (month)11.00 (9.50)12.00 (12.00)Sex (n) Male32 (68.1%)16 (48.5%) Female15 (31.9%)17 (51.5%)Site of onset (n) Limb34 (72.3%)24 (72.7%) Bulbar11 (23.4%)7 (21.2%) Mixed2 (4.3%)2 (6.1%) ALSFRS-R40.00 (8.00)31.00 (15.00)*** δFS0.58 (0.78)1.47 (1.67)***Adipokines Adiponectin (ng/ml)61.83 (14.86)39.23 (10.71)*** Visfatin (ng/ml)3.90 (2.20)4.56 (2.51) Resistin (ng/ml)2.73 (1.56)2.67 (1.37) Chemerin (ng/ml)2.67 (1.19)2.39 (1.57) FGF-21 (pg/ml)442.35 (209.25)534.72 (256.36)*Pro-inflammatory cytokines IL-1β (pg/ml)282.04 (72.12)362.60 (37.44)*** IL-2 (pg/ml)267.81 (66.64)349.68 (39.92)*** IL-6 (pg/ml)113.02 (46.17)129.96 (37.39)** IL-8 (pg/ml)282.24 (121.69)370.52 (83.39)*** TNF-α (pg/ml)300.70 (80.49)393.94 (50.17)***Anti-inflammatory cytokine IL-4 (pg/ml)488.50 (166.47)425.04 (169.07) IL-13 (pg/ml)209.98 (122.98)233.46 (73.35) TGF-β (pg/ml)522.13 (206.00)493.38 (288.60) IL-10 (pg/ml)128.37 (38.61)80.97 (37.52)**** p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. Comparison of basic characteristics, adipokines, and inflammatory factors between ALS survival and death groups. * p < 0.05. ** p < 0.01. *** p < 0.001. Abbreviations: ALS, amyotrophic lateral sclerosis; ALSFRS-R, ALS Functional Rating Scale-Revised; δFS, The rate of disease progression; BMI, body mass index. The relationship between adiponectin, inflammatory factors, and disease progression in ALS patients To further substantiate the correlation between adiponectin, inflammatory factors, and disease progression, a Spearman correlation analysis was conducted on adiponectin, IL-1β, IL-2, IL-6, IL-8, TNF-α, IL-10, ALSFRSR of 1.5 years and δFS of 1.5 years. The results of this study are presented in Fig. 2. ALSFRSR of 1.5 years demonstrated a significant negative correlation with IL-1β (r=−0.72, p < 0.001), IL-2 (r=−0.70, p < 0.001), IL-6 (r=−0.52, p < 0.001), IL-8 (r=−0.63, p < 0.001) and TNF-α (r=−0.69, p < 0.001), while concurrently exhibiting a significant positive correlation with adiponectin (r = 0.70, p < 0.001) and IL-10 (r = 0.65, p < 0.001). Conversely, a significant positive correlation was observed between δFS of 1.5 years and IL-1β (r = 0.77, p < 0.001), IL-2 (r = 0.78, p < 0.001), IL-6 (r = 0.57, p < 0.001), IL-8 (r = 0.7, p < 0.001) and TNF-α (r = 0.74, p < 0.001), while a significant negative correlation was found between δFS of 1.5 years and adiponectin (r=−0.79, p < 0.001) and IL-10 (r=−0.66, p < 0.001). Fig. 2Spearman correlation analysis was performed to examine the relationships between ALSFRS-R-1.5 years, δFS-1.5 years, adiponectin levels, and inflammatory factors. Spearman correlation analysis was performed to examine the relationships between ALSFRS-R-1.5 years, δFS-1.5 years, adiponectin levels, and inflammatory factors. The connection between adiponectin, inflammatory factors, and survival in ALS patients We did a 1.5-year follow-up study to learn more about how adiponectin and inflammatory factors affect the survival of ALS patients. At the end of the study, 33 patients (41.2%) had died, and 47 (58.8%) had survived. A detailed analysis of the results revealed significant differences in ALSFRS-R and δFS between the deceased and surviving groups. Additionally, adiponectin (p < 0.001) and IL-10 (p < 0.001) levels were significantly lower in the group that died. On the other hand, the levels of FGF-21 (p < 0.05), IL-1β (p < 0.001), IL-2 (p < 0.001), IL-6 (p < 0.001), IL-8 (p < 0.001) and TNF-α (p < 0.001) were considerably elevated (Table 1). To further identify risk factors associated with ALS survival, the least absolute shrinkage and selection operator (LASSO) regression method was used to analyze significant variables. LASSO regression identified five variables with non-zero coefficients as significantly associated with ALS survival: ALSFRS-R, δFS, adiponectin, IL-6, and IL-10 (Fig. 3a,b). These results suggest a correlation between adiponectin, inflammatory factors, and survival in ALS patients. Fig. 3(a) A coefficient profile was generated along the log (λ) sequence, with non-zero coefficients selected based on the optimal λ. (b) Ten-fold cross-validation for λ selection. The left and right vertical dotted lines indicate the optimal λ yielding the minimum partial likelihood deviance (λ min) and the λ within one standard error (λ 1se), respectively. To ensure reproducibility, a random seed was set at 773. Based on λ min, 5 variables with non-zero coefficients were ultimately selected as optimal predictors. (a) A coefficient profile was generated along the log (λ) sequence, with non-zero coefficients selected based on the optimal λ. (b) Ten-fold cross-validation for λ selection. The left and right vertical dotted lines indicate the optimal λ yielding the minimum partial likelihood deviance (λ min) and the λ within one standard error (λ 1se), respectively. To ensure reproducibility, a random seed was set at 773. Based on λ min, 5 variables with non-zero coefficients were ultimately selected as optimal predictors. Adiponectin and inflammatory factors are considered as prognostic factors affecting ALS To specifically investigate the relationship between adiponectin, inflammatory factors, and ALS survival and prognosis, we employed a Cox proportional hazards model to obtain specific HRs for these risk variables. We first conducted a univariate analysis on the risk factors identified by LASSO, and the results showed that lower ALSFRS-R scores at baseline (HR = 0.911, 95%CI: 0.880–0.943, p < 0.001), higher δFS (HR = 1.340, 95%CI: 1.192–1.506, p < 0.001), and elevated serum levels of IL-6 (HR = 1.021, 95%CI: 1.007–1.036, p < 0.001) were identified as risk factors for mortality. Conversely, higher serum adiponectin (HR = 0.920, 95%CI: 0.891–0.950, p < 0.001) and IL-10 levels (HR = 0.960, 95%CI: 0.946–0.975, p < 0.001) were associated with prolonged survival (Table 3). Table 3Univariable and multivariable Cox regression analysis in ALS patients.CharacteristicUnivariable modelMultivariable modelHR [95% CI] P HR [95% CI] P IL-6 (pg/ml)1.021 [1.007, 1.036]0.0031.023 [0.997, 1.049]0.081ALSFRS-R0.911 [0.880, 0.943]< 0.0010.820 [0.765, 0.878]< 0.001δFS1.340 [1.192, 1.506]< 0.0011.234 [1.065, 1.430]0.005IL-10 (pg/ml)0.960 [0.946, 0.975]< 0.0010.968 [0.951, 0.986]< 0.001Adiponectin (ng/ml)0.920 [0.891, 0.950]< 0.0010.905 [0.866, 0.946]< 0.001The multivariate model incorporates three covariates: age, sex, and site of onset. ALSFRS-R ALS Functional Rating Scale-Revised, δFS The rate of disease progression, CI confidence interval, HR hazard ratio. Table 3Univariable and multivariable Cox regression analysis in ALS patients.CharacteristicUnivariable modelMultivariable modelHR [95% CI] P HR [95% CI] P IL-6 (pg/ml)1.021 [1.007, 1.036]0.0031.023 [0.997, 1.049]0.081ALSFRS-R0.911 [0.880, 0.943]< 0.0010.820 [0.765, 0.878]< 0.001δFS1.340 [1.192, 1.506]< 0.0011.234 [1.065, 1.430]0.005IL-10 (pg/ml)0.960 [0.946, 0.975]< 0.0010.968 [0.951, 0.986]< 0.001Adiponectin (ng/ml)0.920 [0.891, 0.950]< 0.0010.905 [0.866, 0.946]< 0.001The multivariate model incorporates three covariates: age, sex, and site of onset. ALSFRS-R ALS Functional Rating Scale-Revised, δFS The rate of disease progression, CI confidence interval, HR hazard ratio. Univariable and multivariable Cox regression analysis in ALS patients. The multivariate model incorporates three covariates: age, sex, and site of onset. ALSFRS-R ALS Functional Rating Scale-Revised, δFS The rate of disease progression, CI confidence interval, HR hazard ratio. To adjust for potential confounders and determine the independent predictive value of these biomarkers, we constructed a multivariate Cox regression model and we included three covariates: age, sex, and site of onset. After adjusting for confounding factors, it is worth noting that adiponectin (HR = 0.905, 95%CI: 0.866–0.946, p < 0.001), IL-10 (HR = 0.968, 95%CI: 0.951–0.986, p < 0.001), δFS (HR = 1.234, 95%CI: 1.065–1.430, p = 0.005) and ALSFRS-R (HR = 0.820, 95%CI: 0.765–0.878, p < 0.001) remained strong independent prognostic factors. However, IL-6 (HR = 1.023, 95%CI: 0.997–1.049, p = 0.081) did not reach statistical significance in the final multivariate analysis. Meanwhile, we visualized this result using a forest plot (Fig. 4). Fig. 4Forest plot of various risk factors. The hazard ratios (HR) and 95% confidence intervals (CI) for adiponectin (HR = 0.905, 95%CI: 0.866–0.946, p < 0.001), IL-10 (HR = 0.968, 95%CI: 0.951–0.986, p < 0.001), δFS (HR = 1.234, 95%CI: 1.065–1.430, p = 0.005) and ALSFRS-R (HR = 0.820, 95%CI: 0.765–0.878, p < 0.001). Forest plot of various risk factors. The hazard ratios (HR) and 95% confidence intervals (CI) for adiponectin (HR = 0.905, 95%CI: 0.866–0.946, p < 0.001), IL-10 (HR = 0.968, 95%CI: 0.951–0.986, p < 0.001), δFS (HR = 1.234, 95%CI: 1.065–1.430, p = 0.005) and ALSFRS-R (HR = 0.820, 95%CI: 0.765–0.878, p < 0.001). Prognostic risk level criteria To further transform our multivariate statistical results into a clinically intuitive risk stratification system, we conducted a Kaplan-Meier survival analysis. The cohort was divided into groups based on the median level of each risk factor. Consistent with the Cox model, patients in the high adiponectin group exhibited a significantly prolonged overall survival compared to those in the low group (Log-rank p < 0.0001, Fig. 5a), patients in the high ALSFRS-R and high IL-10 groups exhibited significantly longer overall survival compared to those in the corresponding low groups (Log-rank p = 0.0045, Log-rank p < 0.0001, Fig. 5b,c). In contrast, patients in the high δFS group showed a significantly shorter median survival time than those in the low δFS group (Log-rank P = 0.00053, Fig. 5d). In summary, these parameters serve as reliable, independent indicators capable of effectively discriminating survival outcomes in patients with ALS. Fig. 5The log-rank test was used to compare Kaplan-Meier survival curves for the primary endpoint. (a) A significant difference was observed between the low-risk and high-risk groups for adiponectin (p < 0.0001). (b) A significant difference was observed between the low-risk and high-risk groups for ALSFRS-R (p = 0.0045). (c) A significant difference was observed between the low-risk and high-risk groups for IL-10 (p < 0.0001). (d) A significant difference was observed between the low-risk and high-risk groups for δFS (p < 0.0001). The log-rank test was used to compare Kaplan-Meier survival curves for the primary endpoint. (a) A significant difference was observed between the low-risk and high-risk groups for adiponectin (p < 0.0001). (b) A significant difference was observed between the low-risk and high-risk groups for ALSFRS-R (p = 0.0045). (c) A significant difference was observed between the low-risk and high-risk groups for IL-10 (p < 0.0001). (d) A significant difference was observed between the low-risk and high-risk groups for δFS (p < 0.0001). Discussion ALS is a rare and fatal neurodegenerative disorder. Identifying modifiable risk factors for ALS represents a promising strategy to alleviate the burden of this debilitating condition. Numerous immune markers, including various serum cytokines, have been explored as potential risk factors for ALS severity and survival7–11. A growing body of evidence suggests that inflammatory markers and indicators of nutritional metabolism may serve as reliable prognostic factors for patients with wasting diseases18. However, the specific risk factors for ALS progression and survival remain to be fully elucidated. In this study, we investigated a range of serum biomarkers, including cytokines and adipokines, in ALS patients to assess their impact on disease severity and survival outcomes. These findings are consistent with previous research; our investigation has revealed that both ALSFRS-R and δFS are risk factors contributing to the progression and survival of ALS19,20. The ALSFRS-R is a reliable measure of physical function in ALS patients, assessing their ability to perform daily activities. This methodology is widely used in research, primarily to assess disease severity and monitor progression. δFS indicates a change in the ALSFRS-R slope from disease onset to baseline21. Therefore, it has been demonstrated that both ALSFRS-R and FS are significant risk factors for ALS progression and survival. More importantly, our findings suggest that ALS patients with rapid disease progression have lower levels of adiponectin. Furthermore, adiponectin shows a significant positive correlation with ALSFRS-R and a negative correlation with δFS. Cox regression and Kaplan-Meier (KM) curve analyses suggest that adiponectin is a significant risk factor influencing the survival of ALS patients. Adiponectin, a key adipokine predominantly secreted by adipocytes, plays crucial roles in metabolic homeostasis and inflammation, exhibiting anti-diabetic, antioxidant, and anti-inflammatory properties22,23. First, a substantial body of clinical and animal studies has demonstrated that adiponectin enhances insulin sensitivity. A decrease in serum adiponectin levels indicates reduced insulin sensitivity, a hallmark of insulin resistance24,25. Insulin resistance has been observed in various neurodegenerative diseases and has been suggested to induce the occurrence, development, and exacerbation of neurodegenerative diseases26. Therefore, insulin resistance in ALS may result from decreased adiponectin levels and may play a crucial role in both the onset and progression of the disease, as well as in predicting its prognosis. Second, it has been demonstrated that adiponectin can modulate microglial activities, including phagocytosis and the secretion of proinflammatory cytokines27,28. Moreover, adiponectin has been shown to enhance neuroinflammation through various signaling pathways17,29. Consequently, a decline in adiponectin levels may result in inadequate protection against neuroinflammation in ALS, thereby accelerating disease progression and worsening prognosis. Finally, adiponectin exerts multifunctional effects, one of which is its role in coordinating the regulation of skeletal muscle and skeletal function30. Muscle weakness in ALS patients precedes motor neuron degeneration, and skeletal muscles perform essential functions throughout development31,32, significantly impacting disease progression and prognosis. Therefore, a decrease in adiponectin levels may negatively impact ALS progression and survival by impairing the normal physiological function of skeletal muscles. The present study identified that decreased levels of the anti-inflammatory cytokine IL-10 are associated with the progression and survival of ALS. The beneficial role of IL-10 is supported by Furukawa et al., who found that high IL-10 levels are associated with slower disease progression33. A study in simulated SOD1G93A transgenic mice demonstrated that IL-10 expression in the spinal cord, via a recombinant adeno-associated virus (rAAV) vector, was associated with increased survival duration34. Similarly, the introduction of gene therapy led to significant upregulation of IL-10 in SOD1G93A microglia, resulting in a substantial delay in disease onset and an extension of survival duration35. Furthermore, intramuscular injection of IL-10 has been shown to attenuate disease progression in SOD1G93A models, thereby extending survival rates36. These findings provide further evidence supporting the hypothesis that IL-10 plays a significant role in ALS progression and survival. It is noteworthy that while IL-6 was selected as a potential prognostic feature by LASSO regression, it only exhibited a trend toward significance in the fully adjusted multivariate Cox model (P = 0.081). Recent studies have shown that IL-6 is implicated in the progression of ALS. This may occur because IL-6 exacerbates ALS via the ‘IL-6 trans-signaling’ pathway. IL-6 activates immune cells in the brain, damaging motor neurons, impairing the blood-brain barrier, and accelerating muscle atrophy37–39. This attenuation of statistical significance does not necessarily negate the biological involvement of IL-6 in ALS pathogenesis. Instead, it suggests that the prognostic effect of this pro-inflammatory cytokine might be shared with, or mediated by, other strong clinical covariates such as baseline ALSFRS-R or δFS. More importantly, adiponectin and IL-10 showed strong independent prognostic value, highlighting an interesting possibility that the exhaustion of neuroprotective and anti-inflammatory mechanisms may be a key factor in determining ALS survival more than simply pro-inflammatory responses. Importantly, these findings should be interpreted within the context of established ALS fluid biomarkers, particularly neurofilament light chain (NfL), which is currently regarded as the most robust prognostic biomarker in ALS and the central benchmark in contemporary biomarker validation studies. Although NfL was not measured in our cohort, adiponectin and IL-10 may provide biologically distinct information. Whereas NfL primarily reflects downstream neuroaxonal injury40, adiponectin and IL-10 may capture upstream systemic and immunoregulatory processes that influence disease progression. Recent studies on liquid prognostic biomarkers in ALS have emphasized the need for complementary biomarkers that reflect inflammatory and non-neuronal disease pathways41,42. Notably, glial and neuroinflammatory biomarkers such as CHIT1 and CHI3L1/YKL-40 reflect microglial and astroglial activation43, whereas IL-10 reflects anti-inflammatory regulation and adiponectin indicates a broader neuroprotective-metabolic state. Thus, these biomarkers are complementary rather than redundant. A profile characterized by elevated CHIT1/YKL-40 together with reduced IL-10 or adiponectin may indicate both enhanced inflammatory activation and impaired endogenous protective capacity44, which could help explain differences in disease aggressiveness and survival. Therefore, the role of adiponectin in ALS is not limited to inflammation - its ability to regulate insulin sensitivity and oxidative stress may further promote disease progression, as metabolic disorders are increasingly recognized as driving factors in the pathogenesis of ALS. Combining adiponectin and IL-10 with established central nervous system derived biomarkers such as NfL, CHIT1, and YKL-40 is expected to optimize prognostic models and aid in clinical trial stratification and personalized treatment strategies. However, there are several limitations in our study that should be acknowledged. First, it is important to note that the relatively small sample size may introduce bias, limiting the generalizability and clinical applicability of the findings. This highlights the need for a multicenter, prospective study with a larger cohort. Second, due to the heterogeneity of ALS, and despite adjustments for certain confounding factors, the possibility of unidentified covariates cannot be completely ruled out. Third, it is important to note that only peripheral adiponectin and inflammatory factors were measured, which may not fully represent the levels in the central nervous system, and our survival analysis is based on baseline serum cytokine levels, which may not fully capture the dynamic trajectory of ALS neuroinflammation. Future research needs to confirm these findings through longitudinal biomarker tracking. Finally, the multivariable Cox model is subject to certain limitations, as various variables may exhibit causal relationships in both upstream and downstream directions. In order to clarify this complex causal pathway, future large sample multicentre studies should use mediation analysis or structural equation modeling (SEM) to evaluate the direct and indirect effects of inflammatory factors on survival. Conclusion In summary, our study identified that lower levels of adiponectin and IL-10 are associated with more severe disease, accelerated progression, and reduced survival. These findings provide a robust theoretical foundation for the development of new treatment strategies and strong biomarker support for assessing the prognosis of ALS patients in clinical settings. Materials and methods Patient selection This prospective cohort study included 110 ALS patients diagnosed with possible, probable, laboratory-supported, or definite ALS, according to the revised El Escorial criteria45, who visited the Second Hospital of Hebei Medical University between February 2023 and April 2024. Eligible participants met the following criteria: aged 18–80 years; the ALS patient or their family members were informed and provided written consent. Exclusion criteria included: forced vital capacity (FVC) ≤ 85%; severe articulation disorders that impair communication; severe neurological or psychiatric disorders; and any of the following serious illnesses: acute pneumonia, rheumatoid arthritis, etc. A total of 80 ALS patients who met the eligibility criteria were ultimately included in the study. The present study was conducted with the participation of human subjects and was approved by the Research Ethics Committee of the Second Hospital of Hebei Medical University (Shijiazhuang, Hebei, approval numbers: 2024-R285). Prior to the initiation of the study, the subjects provided their written consent by signing an informed consent form. It is hereby confirmed that all methods employed are in accordance with the relevant guidelines and regulations. Follow-up Follow-up was conducted from the date of cohort inclusion for 18 months or until the occurrence of the endpoint event, with survival as the primary outcome measure. The endpoint was death, defined as either tracheotomy or NIV (Non-Invasive Ventilation) >22 h/day, both considered equivalent to death46,47. Ultimately, 33 patients (41.2%) reached the endpoint, while 47 patients (58.8%) remained alive. Data collection Collect the following data from ALS patients, including sex, age, body mass index (BMI), family history, delayed diagnosis, disease duration (total duration of disease), site of onset, date of onset, and date of tracheotomy surgery. Diagnostic delay defined as the time interval (in months) between the onset of symptoms and diagnosis. The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) was used to assess disease severity. The rate of disease progression (δFS) was calculated as the average monthly reduction in ALSFRS-R prior to study enrollment. To calculate δFS, the following formula was applied: δFS=(48-ALSFRS-R)/symptom duration (months)48. A monthly decrease of more than 1.0 point in ALSFRS-R indicates rapid progression. Therefore, if the progression rate exceeds 1.0 point per month, the patient is categorized as a rapidly progressing patient (Fast group). Conversely, if the progression rate is less than 1.0 point per month, the patient is classified as a slowly progressing patient (Slow group)49–51. Plasma sample collection A total of 80 ALS patients were included in the study. Their blood samples were collected by professional phlebotomists on an empty stomach in the morning and placed into ethylenediaminetetraacetic acid (EDTA) vacuum blood collection tubes. Subsequently, the samples were subjected to immediate centrifugation at ambient temperature at a velocity of approximately 2000 g for a duration of 15 min. Following the centrifugation process, the plasma was extracted, fractionated, and stored in a −80 °C freezer for subsequent analysis. Quantitative detection of plasma adipokines and inflammatory factors in ALS patients was performed using enzyme-linked immunosorbent assay (ELISA). The assay measured adipokines (adiponectin, visfatin, resistin, chemerin, and FGF-21), pro-inflammatory cytokines (IL-1β, IL-2, IL-6, IL-8, and TNF-α), and anti-inflammatory cytokines (IL-4, IL-10, IL-13, and TGF-β). The commercial ELISA kit (Bioswamp, Wuhan, China) was used for detection, and the ELISA analyzer (AMR-100, Hangzhou, China) quantified the optical density at a wavelength of 450 nm. Plasma adipokine and inflammatory factor concentrations were determined according to the manufacturer’s guidelines. Detailed protocols regarding pre-analytical sample processing (including handling time, storage, and exclusion of acute inflammation) and biomarker quantification procedures (including assay vendor details and reproducibility metrics) are provided in the Supplementary Information. Statistical analysis Data analysis was conducted using SPSS v26.0 (IBM Corp., Armonk, NY, USA) and R 4.2.0 (R Core Team). For metric data that conform to a normal distribution, the mean±standard deviation (Mean ± SD) was used to represent the data. Two independent sample tests were used to compare differences between the two groups. Non-normally distributed quantitative data were represented by the median (interquartile range). Non-parametric rank sum tests were used to compare differences between the two groups. For count data, frequency or percentage representation was used, and the chi-square test was employed to compare two groups. To identify optimal predictors and minimize overfitting, variables were selected using least absolute shrinkage and selection operator (LASSO) regression via the “glmnet” package in R. To ensure the reproducibility of our feature selection, a random seed was set (seed = 773). We employed a 10-fold cross-validation to determine the optimal penalty parameter (λ). Features with non-zero coefficients at the optimal λ value (λ min, which yielded the minimum partial likelihood deviance) were selected as the final candidate risk factors for survival in ALS patients. These selected variables were subsequently entered into a multivariate Cox proportional hazards regression model. Concurrently, R software was used to generate a forest plot displaying the hazard ratio (HR) values and 95% confidence intervals (CI) for each risk factor. Finally, Kaplan-Meier curves and log-rank tests were used to evaluate the impact of these risk factors on the survival of ALS patients. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1